CBPO - China Biologic Products Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
81.18
+0.79 (+0.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close80.39
Open80.45
Bid80.00 x 800
Ask82.00 x 1100
Day's Range80.29 - 82.17
52 Week Range60.08 - 107.44
Volume116,992
Avg. Volume217,526
Market Cap3.195B
Beta (3Y Monthly)0.76
PE Ratio (TTM)39.60
EPS (TTM)2.05
Earnings DateFeb 26, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est104.24
Trade prices are not sourced from all markets
  • Markit5 days ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    # China Biologic Products Holdings Inc ### NASDAQ/NGS:CBPO View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $273 million over the last one-month into ETFs that hold CBPO are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    # China Biologic Products Holdings Inc ### NASDAQ/NGS:CBPO View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding CBPO is favorable, with net inflows of $852 million. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire13 days ago

    China Biologic Reiterates Full Year 2018 Financial Forecast

    BEIJING, Jan. 7, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today reiterated its previously revised full year 2018 forecast. Full year 2018 non-GAAP adjusted income from operations is expected to increase in the range of 0% to 2% in RMB terms and non-GAAP adjusted net income is expected to decrease by 2% to 4% in RMB terms over full year 2017 financial results. Excluding TianXinFu, full year 2018 non-GAAP adjusted income from operations is expected to decrease by 16% to 18% in RMB terms and non-GAAP adjusted net income to decrease by 19% to 21% in RMB terms over full year 2017 financial results.

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit29 days ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. Over the last one-month, outflows of investor capital in ETFs holding CBPO totaled $324 million. Index (PMI) data, output in the Healthcare sector is rising.

  • Business Wirelast month

    David Gao Issues Statement Following Decision by the Grand Court of the Cayman Islands

    “I am disappointed that my lawsuit was dismissed and will evaluate all options as I continue my efforts to protect my and other minority shareholders’ interests in the company. “It is unfortunate that the legal process is hindered because of a Cayman law technicality with regard to my standing to file such a lawsuit before the court can hear the substance of the case regarding the improper purpose of the Board’s actions. The Board’s hastily arranged private placement to a small group of handpicked investors, including Centurium Capital, Chairman David Li’s private equity fund, improperly transferred voting power away from the minority shareholders.

  • PR Newswirelast month

    China Biologic Announces Dismissal of Lawsuit Filed in Cayman Islands by Former Chairman

    BEIJING , Dec. 14, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO ) (" China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and China Biologic Products Holdings

    NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Associated Press3 months ago

    China Biologic Products: 3Q Earnings Snapshot

    On a per-share basis, the Beijing-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to 96 cents per share. The biopharmaceutical company posted revenue of $119.1 ...

  • PR Newswire3 months ago

    China Biologic Reports Financial Results for the Third Quarter of 2018

    3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms; Non-GAAP Adjusted Net Income Down 12.7% YoY in RMB terms; Net Income Up 4.1% YoY to $32.9 Million Board of Di rectors Ap proves $100 ...

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The net inflows of $85 million over the last one-month into ETFs that hold CBPO are not among the highest of the last year and have been slowing.

  • PR Newswire3 months ago

    China Biologic Products to Report Third Quarter 2018 Financial Results

    BEIJING , Oct. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding CBPO is favorable, with net inflows of $1.73 billion.

  • Is China Biologic Products Inc. (CBPO) A Good Stock To Buy? Centurium Capital Thinks So
    Insider Monkey4 months ago

    Is China Biologic Products Inc. (CBPO) A Good Stock To Buy? Centurium Capital Thinks So

    We usually stay away from Chinese companies but we came across an interesting idea recently. Earlier this year ex-Warburg Pincus China head launched his own fund, Centurium Capital, targeting to raise up to $1.5 billion.  The fund was set up to invest Chinese consumer and healthcare companies. Hui Li, also known as David Li, was a director […]

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CBPO had net inflows of $7 million over the last one-month.

  • Business Wire5 months ago

    David Gao Confirms Lawsuit Against China Biologic Products to Protect Shareholders’ Best Interests

    Mr. David (Xiaoying) Gao, a shareholder of China Biologic Products Holdings, Inc. (“China Biologic” or the “Company”) (CBPO), today confirmed that he filed a lawsuit against the Company related to its private placement of shares to a select investor group – including a private equity firm formed by Board Chairman David Li. It seeks to void and invalidate the agreements with Centurium Capital Management Ltd., CITIC Capital MB Investment Limited, Hillhouse Capital Management, Ltd. and PW Medtech.

  • PR Newswire5 months ago

    China Biologic Responds to Lawsuit Filed in Cayman Islands by Former Chairman

    "We deeply regret that Mr. David Gao, acting individually in his personal capacity, has attempted to challenge the completion of the private placement that was announced on August 24.  The Company is prepared to fend off meritless lawsuits like this and will take actions to seek actual and punitive damages from Mr. Gao in connection with his ill-intended lawsuit as well as any damages caused by breaches of his employment agreement. The Company continues to believe that the private placement transaction referred to in the lawsuit is beneficial to shareholders, through the additional capital and strategic partnerships which it will result in.

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit5 months ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding CBPO totaled $1.57 billion.

  • Reuters5 months ago

    China Biologic rejects $3.9 bln bid from former CEO

    China Biologic Products Holdings Inc rejected a $3.9 billion offer from a consortium led by its former chief executive on Friday and said an affiliate of CITIC Capital had also withdrawn a competing bid. The consortium, which included China Biologic's former CEO David Gao, GL Capital Group, Bank of China Group Investment Ltd and CDH Investments, said on Monday it had offered $118 per share, $8 more than the CITIC unit's bid.

  • Business Wire5 months ago

    Leading Investor Group Issues Statement Following China Biologic’s Dilutive Private Placement of Shares

    A consortium composed of Mr. David (Xiaoying) Gao, GL Capital Group, Bank of China Group Investment Limited and CDH Investments (the “Consortium”) today issued the following statement following China Biologic Products Holdings, Inc.’s (“China Biologic” or the “Company”) (CBPO) decision to conduct a dilutive private placement and reject the Consortium’s non-binding proposal to acquire all of the outstanding common shares of the Company for US$118.00 per share in cash. The Consortium’s proposal represented an approximate 30% premium to China Biologic’s closing share price on August 16, 2018, the last trading day before its proposal was conveyed. “We are deeply disappointed that China Biologic's Board has rejected our compelling proposal to deliver immediate and significant value to all shareholders.

  • Here's Why China Biologic Products Stock Dropped Today
    Motley Fool5 months ago

    Here's Why China Biologic Products Stock Dropped Today

    After receiving two buyout offers this summer, the company forged its own path forward -- one that stuffs the balance sheet with around $590 million.

  • Reuters5 months ago

    BRIEF-PW Medtech Group To Purchase 800,000 China Biologic Products Shares For $80.72 Mln

    Aug 24 (Reuters) - PW Medtech Group Ltd: * CO TO PURCHASE 800,000 CHINA BIOLOGIC PRODUCTS (CBPO) SHARES, AT A PRICE OF US$100.9 PER CBPO SHARE * AGGREGATE PURCHASE PRICE FOR CBPO SHARES SHALL BE $80.72 ...